CRSP Crispr Therapeutics Ag

$0.00 (0.00%)

CRSP Stock Analysis Overview

What this means: Crispr Therapeutics Ag (CRSP) gets an Overall Rank of 51, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. CRSP's 51 means that it ranks higher than 51% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Crispr Therapeutics Ag (CRSP) Analyst Forecast

Next 12 months ➝MEAN$93.77+4.00%HIGH$140.00+55.28%LOW$31.00-65.62%Current Price$90.1652-week High$111.9052-week Low$32.30
  • Last Price$90.16
  • Previous Close$90.16
  • Change $0.00
  • Open$97.00
  • Volume1,962,500
  • Avg. Volume (100-day)1,034,061
  • Market Capitalization$6B
  • Days Range $88.00 - $97.10
  • 52-week Range $32.30 - $111.90
  • Dividend Yield
  • Ex. Dividend Date
  • P-E196.2
  • EPS0.47
  • Earnings Date10/26/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta1.836
  • PEG Ratio
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.